PRKCI and renal cell carcinoma: Because of the dependent nature of PKC-ι and PKC−ζ, and their association with c-Myc, PKC-ζ can also be used as a viable target to disrupt c-Myc expression in RCC using a PKC-ζ specific inhibitor, which merits further research.